Stock Forecast

  Adial Pharmaceuticals, Inc. ( ADIL) Stock. Should you Buy or Sell?    $ 0.52

0.01 (1.89 %)



Adial Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol ADIL
Price $0.52
Beta 0.400
Volume Avg. $775.4 thousand
Market Cap $13.44 M
52 Week Range $0.43 - $5.08


Adial Pharmaceuticals, Inc. opened the day at $0.52 which is +'1.89 % on yesterday's close. Adial Pharmaceuticals, Inc. has a 52 week high of $5.08 and 52 week low of $0.43, which is a difference of $4.65. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $13.44 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Adial Pharmaceuticals, Inc. for $13.44 M, it would take 15 years to get your money back. Adial Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Adial Pharmaceuticals, Inc. Stock Forecast - Is Adial Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreStrong Sell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.748
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing Adial Pharmaceuticals, Inc.


Price Book Value Ratio 1.588 Price To Book Ratio 1.588
Price To Sales Ratio 0.000 Price Earnings Ratio -0.748


How liquid is Adial Pharmaceuticals, Inc.


Current Ratio 5.324
Quick Ratio 4.905


Debt


Debt Ratio 0.271 Debt Equity Ratio 0.372
Long Term Debt To Capitalization 0.022 Total Debt To Capitalization 0.028



Latest news about Adial Pharmaceuticals, Inc.


Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher

Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Date : 01/09/2022

Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).

Date : 26/08/2022

Adial Clinical Trial: A Fluff Or A Win?

Onward Phase III Clinical Trial of Adial Pharmaceutical's AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in.

Date : 22/08/2022

What's Going On With Adial Pharmaceuticals Stock Today?

Shares of small-cap penny stock Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares are trading about 20.5% lower at $1.46 per share Wednesday morning. The company announced topline results for its Onward Phase 3 trial for AD04 in patients with Alcohol Use Disorder.

Date : 20/07/2022

Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET

Date : 18/07/2022





About Adial Pharmaceuticals, Inc.


CEO : Mr. William Stilley
Sector : Healthcare
Industry : Biotechnology

Website : https://www.adialpharma.com

Exchange : NASDAQ Capital Market

Description :

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.


My Newsletter

Sign Up For Updates & Newsletters